Abstract
The use of immunotherapy in the treatment of non-Hodgkin lymphomas has improved response rates and survival in this population. With widespread rituximab use and longer-term follow-up of patients receiving rituximab, infectious complications are increasing. These complications are of great concern in the AIDS-related lymphoma population. We review the data on activity and infectious toxicity of rituximab to date and as it pertains to the treatment of AIDSrelated non-Hodgkin lymphoma and Multicentric Castlemans disease.
Keywords: AIDS, AIDS related Lymphoma, HAART, HIV, JC Polyoma virus associated progressive multifocal leukoencyphalopathy, Multicentric castleman's disease, non-hogdkin's lymphoma, rituximab, lymphoma, hepatitis B, hepatitis C, dose adjusted EPOCH, CHOP, CODOX-IVAC, magrath regimen, kaposi sarcoma, bortezomib
Current Drug Delivery
Title: Clinical Use of Rituximab in Patients with HIV Related Lymphoma and Multicentric Castlemans Disease
Volume: 9 Issue: 1
Author(s): Erin Reid, Ajay Nooka, Jawaunna Blackmon and Mary Jo Lechowicz
Affiliation:
Keywords: AIDS, AIDS related Lymphoma, HAART, HIV, JC Polyoma virus associated progressive multifocal leukoencyphalopathy, Multicentric castleman's disease, non-hogdkin's lymphoma, rituximab, lymphoma, hepatitis B, hepatitis C, dose adjusted EPOCH, CHOP, CODOX-IVAC, magrath regimen, kaposi sarcoma, bortezomib
Abstract: The use of immunotherapy in the treatment of non-Hodgkin lymphomas has improved response rates and survival in this population. With widespread rituximab use and longer-term follow-up of patients receiving rituximab, infectious complications are increasing. These complications are of great concern in the AIDS-related lymphoma population. We review the data on activity and infectious toxicity of rituximab to date and as it pertains to the treatment of AIDSrelated non-Hodgkin lymphoma and Multicentric Castlemans disease.
Export Options
About this article
Cite this article as:
Reid Erin, Nooka Ajay, Blackmon Jawaunna and Jo Lechowicz Mary, Clinical Use of Rituximab in Patients with HIV Related Lymphoma and Multicentric Castlemans Disease, Current Drug Delivery 2012; 9 (1) . https://dx.doi.org/10.2174/156720112798376005
DOI https://dx.doi.org/10.2174/156720112798376005 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
FDG-PET Imaging in Large Vessel Vasculitis and Polymyalgia Rheumatica: A Personal View
Current Immunology Reviews (Discontinued) Design, Synthesis and Anticancer Activity Against the MCF-7 Cell Line of Benzo-Fused 1,4-Dihetero Seven- and Six-Membered Tethered Pyrimidines and Purines
Current Medicinal Chemistry Pharmacological Properties and Therapeutic Possibilities for Drugs Acting Upon Endocannabinoid Receptors
Current Drug Targets - CNS & Neurological Disorders Interactions of the Aryl Hydrocarbon Receptor with Inflammatory Mediators:Beyond CYP1A Regulation
Current Drug Metabolism Innovative Drug Delivery Systems for the Administration of Natural Compounds
Current Bioactive Compounds Prognostic and Predictive Biomarkers in Cancer
Current Cancer Drug Targets MicroRNA Regulatory Network in Human Colorectal Cancer
Mini-Reviews in Medicinal Chemistry Dry Eye Disease: Present Challenges in the Management and Future Trends
Current Pharmaceutical Design Radiation-Induced Extracranial Carotid Stenosis
Vascular Disease Prevention (Discontinued) The Link Between Conventional and Novel Anti-Cancer Therapeutics with Thrombotic Microangiopathy
Drug Metabolism Letters Pathophysiological and Clinical Aspects of Iron Chelation Therapy in MDS
Current Pharmaceutical Design Overview of Mechanisms of Cancer Stem Cell Drug Resistance
Current Signal Transduction Therapy Editorial (Thematic Issue: Oncoviruses and Head and Neck Cancer: An Impending Facts)
Recent Patents on Biomarkers Proteasome Inhibitors and Modulators of Angiogenesis in Multiple Myeloma
Current Medicinal Chemistry Nitric Oxide and Pancreatic Cancer Pathogenesis, Prevention, and Treatment
Current Pharmaceutical Design Subject Index to Volume 7
Combinatorial Chemistry & High Throughput Screening Amplicons as Vaccine Vectors
Current Gene Therapy Chromosomal Abnormalities, Cancer and Mouse Models The Critical Role of Translocation-Associated Genes in Human Cancer
Current Genomics Specific Biologic Therapy with Tumor Necrosis Factor Inhibitors in Patients with Inflammatory Myopathy
Current Rheumatology Reviews Development and Assessment of Conventional and Targeted Drug Combinations for Use in the Treatment of Aggressive Breast Cancers
Current Cancer Drug Targets